With respect to CF testing, it was shown that infants with raised IRTs in the first few months of life were more likely to have CF than those with normal results.' Infants whose IRT remained raised after a repeat test had their sweat electrolytes analysed to determine their CF status as this was regarded as the definitive test for CF. 5 However, IRT levels could also be influenced by a number of other factors, including respiratory infections, gut abnormalities, or premature birth6 and hence a large number of false positives were detected by this system.
The gene that is mutated in patients with CF, the cystic fibrosis transmembrane conductance regulator (CFTR), was discovered in September of 1989.7 A 3 bp deletion in the genomic DNA resulting in the removal ofthe amino acid phenylalanine at position 508 in the protein (AF508) was shown to be the most common mutation causing CF. The AF508 mutation accounts for approximately 70% of CF gene mutations in our population. This varies depending on the ethnic group (CF consortium). In July 1990, the DNA test for AF508, which can be performed directly on dried blood spot samples, was made part of the newborn screening programme in Victoria.
This paper presents the Victorian newborn screening results for CF up to 1993 as well as specifically tracking the process of identification of subjects with CF over a two year time span (1991) (1992) . The uptake ofprenatal diagnosis by the families identified through newborn screening is also examined and is shown to increase in comparison to families where the CF affected child was diagnosed before the advent of newborn screening.
Methods and materials
Primers flanking the 3 bp deletion, AF508,7 amplify a 98 bp fragment in normal people while a 95 bp fragment is present in people with the deletion. The dried blood spot samples are eluted in a mixture of water, standard 1 x buffer (6 7 mmolIl Tris-HCl pH 8-8, 1-66 mmol/l (NH4)2SO4, 0-045% Triton X-100, 20 jg/ml gelatin), 2 mmol/1 MgCl2 and 0-1% Triton X-100 at 37'C for 30 minutes. Samples are boiled for five minutes and placed on ice briefly. A mixture of dNTPs (final concentration 0-2 mmol/l), 500 ng each primer, and 2-5 units Taq polymerase is added in a final 100,l reaction and overlaid with paraffin oil. The PCR is performed for 27 cycles for one minute at 95°C, one minute at 63°C, and two minutes at 72°C in a thermal cycler. A 20 jl aliquot of the PCR product is run on a 10% non-denaturing polyacrylamide gel (NOVEX, Australia) and visualised by ethidium bromide staining. The two fragments are easily resolved.
Sample data were analysed from the newborn screening laboratory for the last four years. Data before 1990, when DNA testing began, were obtained from personal records ofpatients seen for CF testing in the genetics clinic of the Royal Children's Hospital. This was cross referenced with data on all patients seen by the 2B) . Ten were homozygous AF508 and 51 were AF508 heterozygotes. Of these heterozygotes, 39 had normal sweat tests, nine were positive (and went on to have further testing as outlined in fig 1) , and three had no sweat test. Of these one had died, one infant had a mother with CF, and one had a sib with CF. There is no indication why they were followed no further. Again five infants were identified with MI and all were shown to be 29
affected vice. The years 1986-1988 were the years before newborn screening and 1989-1991 were the years after screening was introduced. Familre sweat tested ies with more than one affected child had these lad a family his-children without prenatal diagnosis and hence he system, and were considered as "no CVS" if the birth fell )ur infants were into the two and a half year time interval. The te normal IRTs number of CF affected children listed for each re 13 , which were all confirmed. In total, 84/102 were followed up with 100% accuracy.
Requests for carrier testing have become commonplace since the discovery of the AF508 mutation, its relatively high frequency in the population, and the ease of performing the test. Many of the people requesting carrier testing are relatives of the infants recently diagnosed by newborn screening. Carrier testing is only performed in families with known CF affected subjects or in families where the infant was found to be heterozygous for AF508 on newborn screening but had a negative sweat test result. Three hundred and fifty six people (to 30.9.93) have been tested for AF508 and three exon 11 mutations: G542X, G551D, and R553X. This has identified three carrier couples, two who have since used prenatal diagnosis and one who has as yet not used prenatal diagnosis. In another couple, the partner was shown to be a carrier while the sib of the affected child had his risk reduced to zero as he had not inherited the CF mutation in the family.
Discussion
Newborn screening for cystic fibrosis was introduced into Victoria in 1989.3 The screening test comprised an immunoreactive trypsinogen (IRT) assay on the newborn dried blood spot sample, followed by another IRT on a 28 day sample for those whose initial IRT fell within the top 0-7%. The discovery of the CF gene in 19897 enabled direct mutation testing to be incorporated into the screening assay. In the new scheme, which was introduced in 1991, the second IRT assay was replaced by an assay for the most common CF mutation, AF508 (70% of CF mutations). This rapid, simple, and accurate assay can be performed directly on the newborn dried blood spot sample89
and has been incorporated in other newborn screening programmes." A separate DNA extraction step is not required and the need for a second sample collection is eliminated. Testing for mutations other than AF508 has not been included in our screening programme. Analysis of our CF data shows that the next most common mutation, G55 ID (5% of CF mutations), was found in only seven cases. However, all were compound heterozygotes for AF508 and so would be detected by the current protocol.
Farrell and Mischler"2 identified some areas ofconcern with regard to newborn screening for CF. In their hands, the IRT test had suboptimal sensitivity and inadequate positive predictive value, thereby leading to adverse effects, particularly in the false positive families. They noted that the discovery of the CF gene would possibly solve some of these problems. They concluded that the costs of screening did not significantly add to the costs of care for CF patients, but after only five years of randomised investigation, it was too soon to reach conclusions on whether newborn screening conferred any benefits in terms of reduced admissions to hospital and better prognosis.
Newborn We feel that some of these criticisms have been met by the new screening protocol we have adopted. The high false positive rate in the original protocol resulted from the need to obtain a second sample from infants in the top 0-7% of IRT results. This has been eliminated by performing mutation analysis on the first dried blood spot sample. This has reduced the need to contact parents, which in the past caused much ofthe parental anxiety, from 0-7% down to 0O08% of infants tested. Only those infants found to be heterozygous for AF508 require a confirmatory sweat test, since homozygosity for AF508 is, itself, confirmatory of CF. This knowledge is also of great assistance in reducing parental anxiety by appropriate counselling, in contrast to the original screening protocol in which the indication for a second sample or a sweat test was the non-specific rise of IRT.
We have shown that the newborn screening test for CF has dramatically reduced the age at diagnosis (fig 3A, B 
